Mallinckrodt plc, a prominent global specialty pharmaceutical firm, has announced a major deal with CVC Capital Partners, one of the world’s leading investment firms. Under the newly signed definitive agreement, CVC Capital Partners Fund IX will acquire Mallinckrodt’s Therakos business for approximately $925 million, subject to customary adjustments. The sale marks a significant move for […]
In a strategic move to broaden its pharmaceutical offerings, UK-based Mallinckrodt has announced the acquisition of Sucampo Pharmaceuticals, including its commercial and developmental assets, for approximately $1.2 billion. This acquisition also involves the assumption of $360 million of Sucampo’s debt, signaling a significant investment by Mallinckrodt into expanding its specialty pharmaceutical and rare disease sectors. […]
